多发性硬化症患者里图西马布的长期不良事件,伊斯法罕,伊朗
Ali Rahimisadegh1,2, Omid Mirmosayyeb1,2, Shakiba Houshi1,2
1Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
International journal of preventive medicine
|July 29, 2025
概括
瑞图西马布 (RTX) 治疗对于多发性硬化症患者来说是安全的,并且耐受性良好,大多数不良事件是轻微的感染. 这种治疗在患有较长疾病持续时间的患者中改善了残疾.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
背景情况:
- 在患有多发性硬化症 (pwMS) 患者中评估rituximab (RTX) 治疗的不良事件 (AEs).
- 使用伊朗多发性硬化中心临床数据的观察性研究 (2015年1月至2018年1月).
研究的目的:
- 在pwMS中评估RTX的安全性和耐受性.
- 评估RTX对残疾进展和复发率的影响.
主要方法:
- 307名pwMS接受了RTX治疗.
- 初始剂量:2克RTX (四个500毫克IV剂6小时).
- 维护:每6个月两次500mgRTX剂量 (每剂量4-6小时).
主要成果:
- 39.4%的患者至少出现了一种副作用,主要是轻微的尿道和呼吸道感染.
- 扩展残疾状况尺度 (EDSS) 在疾病持续时间<3年内保持稳定.
- 在疾病持续时间超过3年的患者中观察到显著的EDSS改善 (P=0.015).
结论:
- 瑞图西马布 (RTX) 对多发性硬化症 (MS) 患者的耐受性很好,并且安全.
- 副作用通常是轻微的,包括轻微的输液反应和感染.
- 在长期的MS中,RTX显示了改善长期MS残疾的潜力.
更多相关视频
09:54Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020
3.6K
04:50Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
343
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
423
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
423
Multiple Sclerosis l: Introduction
20
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
20
